Video Transcription
Aritz Zamacola 00:03
Eric, hello, everyone. I'm Aritz Zamacola. I'm the CEO and co-founder of Resolve Stroke. Imaging significantly enhances the key insights you can extract from raw ultrasound data while preserving all the key characteristics of its beautiful imaging modalities: number one, safety, portability, accessibility. We are doing that with a stroke. Now it's possible, and we are starting with no imaging; it's just the beginning. Today, lack of imaging kills, but quite sure, early diagnosis can cure more deadly diseases, unfortunately, and stroke is a prime example of that, with just one in four others likely to experience a stroke. Timely detection will be very crucial. Unfortunately, today, current imaging tools fall short for bedside diagnosis, fall short for diagnosis in the ambulances, and at patient bedside in the hospital, and the result is that 14 million stroke patients will be diagnosed too late every year. To implement wide pre-screening, to provide the diagnostics at the right time and the right place, and thus save lives, we need to increase by 100-fold the access to video of CT scans or MRIs. The solution lies in enhancing the raw data that you can extract from raw ultrasound data today. With just 10% of the raw data extracted and then treated in the ultrasound card, we are able to achieve remarkable results. And you know that—what if we could harness and extract and treat 100% of the raw ultrasound data? That's not just a dream. That's not just a slide. For example, our co-founder has already demonstrated in Nature that we are able to improve by 10 the evolution of raw ultrasound, of ultrasound in general, and that's possible now, and it bypasses the limits of the physics results. Why are we able to do that now? Because now you have to see the ultrasound card like a computer, where you are able to play with the software to manipulate this data, and we are now able to replicate the beautiful story of ultrasonic cardiology in other segments, thanks to this manipulation with software. And we are starting with no imaging. We decided to create the company two years ago because the hardware was finally maintained to integrate our first engines inside our first card called Silver Air. But we designed our software, our engines from the beginning to be integrated into other hardware systems. What we are doing, in fact, is building software, an operating system from raw data to the collection of the raw data to the endpoints for the physicians, for the patients. For example, with our first engine, with one acquisition of our ultrasound, we collect 300 gigabytes of data, and then we have endpoints, very good endpoints. We are not just revolutionizing specific medical workflows at patient bedside in the hospital. We have now much more data, and with this data, we can pioneer a whole new category of predictive insights. We have a very pragmatic approach. As a young startup, we focus on neurocritical care, neuro intensive care units with first brain monitoring. Here, we are developing stroke biomarkers with our data, and we are investigating other areas, such as monitoring of transplants just after surgery. But the key opinion leaders are already identifying new opportunities, such as monitoring neurodegenerative diseases and monitoring tumor aggressiveness. For example, we have made significant strides fast-tracking the introduction of the first D-brain ultrasound device called Siever, introducing our first engine called ARIS North Street. This Siever is now available for clinical research. With Siever, we are, in fact, filling gaps where there is no alternative for our first use case in neurocritical care. The idea is to replace conventional loops; it's a better alternative to conventional loops and to invasive probes. For instance, an area of picture of our device in intensive care units in your room with our physician is already a game changer because, with ultrasound, we are able to provide detailed morphology mapping of brain vascularization. We are able to provide perfusion like in CT scans, and we are able to provide non-user dependent velocity mapping—that's really important to assess treatment in the diagnosis at patient bedside. Siever could already bring significant medical economic benefits to hospitals. In fact, it enhances the visualization of MRI and CT scans, especially with outpatient care; it reduces the transportation costs and associated risks for the patient, and more importantly, it helps shorten hospital stays by accelerating treatment because it's a bedside tool. Why are we able to do that at Resolve Stroke? In fact, we are able to do that because we can bring together physicists, physicians, and industry leaders. For example, our co-founder Olivier Couture is one of the most famous physicists in the world for ultrasound. We have Professor Anton from a medical school. We have industry veterans such as Bryan Makisch, former vice president of general imaging ultrasound at GE Healthcare globally. And we are able to do that because we bring together this type of profiles. We are, in fact, transforming care by expanding the global imaging market into new areas, into blue oceans, starting with no monitoring. But in our view, our data, our biomarkers, have the potential to create companion diagnostic tools, and that's our next step. As I mentioned earlier, we are able to integrate our software into other hardware, but we have a pragmatic approach here. We have a direct sales model. At the beginning, we are able to sell the comprehensive device, but we have in mind to put our software into other hardware systems. But beyond this, royalty-based revenue is quite basic for AI in ultrasound. Our biomarkers have the potential to foster value-based partnerships for healthcare providers and for payers. We have already a strong demand for clinical partnerships in Europe and in the US; they want co-development. We are focusing on our first use case, ICUs, adult ICUs, for neuro monitoring at patient bedside. But we have demand for pediatric monitoring. We have demand for monitoring transplants after the surgery, and so on. It underscores the urgency and value of our products and our technologies. And to conclude, we have now access to this amazing data. So if you are a physician, if you are in med tech or pharma, and you see an opportunity to have access to this data, feel free to reach out. We had our first precision last year, 2 million zero precision last year. And given the amazing results we have with our first clinical trials, we co-developed our first product called Siever. We want now to accelerate. So if you can help us to accelerate, feel free to contact me. Thank you very much. Applause.
